PMID- 29029457
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 39
DP  - 2017 Sep 12
TI  - Prognostic relevance of protein expression, clinical factors, and MYD88 mutation 
      in primary bone lymphoma.
PG  - 65609-65619
LID - 10.18632/oncotarget.19936 [doi]
AB  - Primary bone lymphomas (PBLs) are composed of malignant lymphoid cells presenting 
      in osseous sites, without supra-regional lymph node or extranodal involvement. We 
      systematically characterized the immunophenotype and the myeloid differentiation 
      factor 88 (MYD88)-L265P gene mutation status in PBL. Clinical data from 19 
      patients with PBL treated at Nanjing Drum Tower Hospital between 2009 and 2015 
      were analyzed retrospectively. Protein expression patterns were identified 
      immunohistochemically, and MYD88 mutation was assessed using polymerase chain 
      reaction and direct DNA sequencing. Fifteen patients presented with diffuse large 
      B-cell lymphoma. Clinical factors favoring a good prognosis were an age < 60 
      years and rituximab treatment. B-cell lymphoma 2 expression was detected in 5/15 
      diffuse large B-cell lymphoma patients, and was associated with a poor prognosis 
      in a univariate model. Janus kinase/signal transducer and activator of 
      transcription 3 (JAK/STAT3) signaling factors were upregulated in PBLs. All 
      eighteen evaluable PBL samples harbored wild-type MYD88. These data thus suggest 
      that age and rituximab treatment are independent prognostic factors determining 
      overall survival, and that activation of JAK/STAT3 signaling may promote the 
      pathogenesis of PBL. Moreover, the absence of MYD88-L265P mutation in PBL 
      indicate there are distinct pathogenetic backgrounds among extranodal lymphomas.
FAU - Xu, Yong
AU  - Xu Y
AD  - Department of Hematology, Affiliated Drum Tower Hospital of Nanjing University 
      Medical School, Nanjing, China.
FAU - Li, Jian
AU  - Li J
AD  - Department of Hematology Oncology, Children's Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Ouyang, Jian
AU  - Ouyang J
AD  - Department of Hematology, Affiliated Drum Tower Hospital of Nanjing University 
      Medical School, Nanjing, China.
FAU - Li, Juan
AU  - Li J
AD  - Department of Hematology, Affiliated Drum Tower Hospital of Nanjing University 
      Medical School, Nanjing, China.
FAU - Xu, Jingyan
AU  - Xu J
AD  - Department of Hematology, Affiliated Drum Tower Hospital of Nanjing University 
      Medical School, Nanjing, China.
FAU - Zhang, Qiguo
AU  - Zhang Q
AD  - Department of Hematology, Affiliated Drum Tower Hospital of Nanjing University 
      Medical School, Nanjing, China.
FAU - Yang, Yonggong
AU  - Yang Y
AD  - Department of Hematology, Affiliated Drum Tower Hospital of Nanjing University 
      Medical School, Nanjing, China.
FAU - Zhou, Min
AU  - Zhou M
AD  - Department of Hematology, Affiliated Drum Tower Hospital of Nanjing University 
      Medical School, Nanjing, China.
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Hematology, Affiliated Drum Tower Hospital of Nanjing University 
      Medical School, Nanjing, China.
FAU - Zhang, Cuiling
AU  - Zhang C
AD  - Department of Hematology, Affiliated Drum Tower Hospital of Nanjing University 
      Medical School, Nanjing, China.
FAU - Xu, Yueyi
AU  - Xu Y
AD  - Department of Hematology, Affiliated Drum Tower Hospital of Nanjing University 
      Medical School, Nanjing, China.
FAU - Li, Ping
AU  - Li P
AD  - Department of Hematology, Affiliated Drum Tower Hospital of Nanjing University 
      Medical School, Nanjing, China.
FAU - Zhou, Rongfu
AU  - Zhou R
AD  - Department of Hematology, Affiliated Drum Tower Hospital of Nanjing University 
      Medical School, Nanjing, China.
FAU - Chen, Bing
AU  - Chen B
AD  - Department of Hematology, Affiliated Drum Tower Hospital of Nanjing University 
      Medical School, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20170804
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5630357
OTO - NOTNLM
OT  - JAK/STAT
OT  - MYD88
OT  - primary bone lymphoma
COIS- CONFLICTS OF INTEREST The authors have no competing interests.
EDAT- 2017/10/17 06:00
MHDA- 2017/10/17 06:01
PMCR- 2017/09/12
CRDT- 2017/10/15 06:00
PHST- 2017/05/25 00:00 [received]
PHST- 2017/07/25 00:00 [accepted]
PHST- 2017/10/15 06:00 [entrez]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/10/17 06:01 [medline]
PHST- 2017/09/12 00:00 [pmc-release]
AID - 19936 [pii]
AID - 10.18632/oncotarget.19936 [doi]
PST - epublish
SO  - Oncotarget. 2017 Aug 4;8(39):65609-65619. doi: 10.18632/oncotarget.19936. 
      eCollection 2017 Sep 12.